

## TRANSFUSION MEDICINE

## CBS Produced Pathogen Reduced Plasma

Date effective: November 10, 2025

### Background Information:

To provide an additional layer of product safety, as per [Customer Letter #2025-32](#), Canadian Blood Services (CBS) aims to introduce pathogen-reduced components and products, wherever possible.

The INTERCEPT Blood System (Cerus Corporation) for pathogen inactivation reduces the risk of transfusion-transmitted infections and was approved by Health Canada in 2016. This technology inactivates a broad spectrum of enveloped and nonenveloped viruses, Gram-positive and -negative bacteria, spirochetes, and parasites, in addition to potentially harmful residual donor white blood cells in whole blood-derived or apheresis plasma. Treating blood components with Cerus' INTERCEPT technology enhances their safety profile and was previously implemented in platelet processing at Canadian Blood Services in 2022.

### Change in Test Procedure:

**Effective November 10, 2025**, all Manitoba blood banks that store and distribute apheresis plasma will transition their inventories to CBS produced **pathogen-reduced apheresis plasma (psoralen-treated)**.

There is no immediate impact to our plasma inventory as **solvent detergent (S/D) plasma will remain the primary plasma distributed from our blood banks**. However, moving forward, there will be instances where psoralen-treated apheresis plasma may be seen in circulation.

### References/Resources:

[CBS Circular of Information – Pathogen Reduced Plasma Components](#)  
[Transfusion Manitoba Website – Product Monographs](#)

### Patient Impact:

Additional patient contraindications may be considered – *Please refer to the references above for further information*

### More Information:

[CBS Professional Education – Apheresis Frozen Plasma, Psoralen-Treated](#)

### Contact Information:

Charlie Cacapit, Technical Director, Transfusion Medicine  
Shared Health Diagnostic Services  
[ccacapit@sharedhealthmb.ca](mailto:ccacapit@sharedhealthmb.ca)

Charles Musuka, Medical Director, Transfusion Medicine  
Shared Health Diagnostic Services  
[cmusuka@sharedhealthmb.ca](mailto:cmusuka@sharedhealthmb.ca)